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Abstract.  30 
 31 
Background: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive 32 
protein (CRP) and serum amyloid-A (SAA). Increased Hp concentrations may be 33 
induced by endogenous or exogenous glucocorticoids in dogs. Objectives: To assess 34 
whether control of HAC affects the concentrations of Hp, CRP, SAA, alkaline 35 
phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used 36 
to assess control of HAC following trilostane treatment, and whether a combination of 37 
these tests offers a valid method of assessing disease control.  Methods: Hp, CRP, 38 
SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before 39 
and after treatment with trilostane. Adequate control of HAC was defined as post 40 
ACTH cortisol <150 nmol/l. Results: Significant reductions in Hp, ALKP, 41 
cholesterol and SAA (p<.05) but not of CRP were found after control of HAC. Only 42 
Hp, Cholesterol and ALKP were moderately informative (Se & Sp>0.7) of disease 43 
control when compared to ACTH stimulation test. SAA and CRP were unhelpful (Se 44 
& Sp<0.7). The analysis of the combination of the analytes did not improve the 45 
correlation with ACTH stimulation test. Clinical relevance: Relying on these 46 
analytes does not provide additional information over ACTH stimulation test results 47 
when assessing control of HAC treated with trilostane.  48 
 49 
Key words: Acute phase proteins, alkaline phosphatase, canine, 50 
hyperadrenocorticism, trilostane.  51 
 52 
Introduction 53 
Following injury, cytokines induce changes in the concentrations of some 54 
glycoproteins (acute phase proteins –APPS) synthesised primarily by the liver, APPS 55 
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include haptoglobin (Hp), C-reactive protein (CRP), serum amyloid-A (SAA), 56 
cerulopasmin, α1-acid glycoprotein and fibrinogen (Ceron and others 2005). The 57 
pattern of APPS concentration varies with the species and nature of the injury 58 
(Eckersall and others 1999).  APPS are considered a useful tool for diagnosis, 59 
prognosis and monitoring response to treatment in human medicine (Child and others 60 
1978, Kushner and Mackiewicz 1987, Thomson and others 1992).  The availability of 61 
validated commercial veterinary kits has increased their use in non-human species.  62 
  63 
Hyperadrenocorticism (HAC) is a commonly diagnosed canine endocrinopathy 64 
(Reusch and Feldman 1991). Trilostane (Vetoryl, Dechra Veterinary Products Ltd, 65 
Shrewsbury, UK), is currently, the only licensed drug for use in dogs with HAC in the 66 
UK. Trilostane a reversible competitive inhibitor of 3β-hydroxysteroid dehydrogenase 67 
blocks steroid biosynthesis in the adrenal gland, thereby inhibiting cortisol 68 
production. The ACTH stimulation test is currently recommended to monitor HAC 69 
treatment (Neiger and others 2002, Ruckstuhl and others 2002, Herrtage 2004). 70 
 71 
Serum Hp concentrations are increased by endogenous and exogenous glucocorticoids 72 
in dogs (Harvey and West 1987, Martinez-Subiela and others 2004).   This has been 73 
attributed to direct steroid induction (McGrotty and others 2003).  Exogenous 74 
glucocorticoids do not affect the concentrations of other APPS such as CRP and SAA 75 
(Thomson and others 1992). Changes in CRP and SAA in dogs with 76 
hyperadrenocorticism have not been previously reported. We have previously shown 77 
that Hp is increased in dogs with HAC whilst dogs that have been treated for HAC 78 
have lower (though still increased) concentrations of Hp (McGrotty and others 2005). 79 
 80 
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Serum alkaline phosphatase (ALKP) activity and cholesterol are the most consistently 81 
increased biochemical parameters reported in dogs with uncontrolled HAC (76% and 82 
90% of the cases respectively) (Ling and others 1979). Both these parameters have 83 
been shown to decrease significantly following treatment (Ruckstuhl and others 2002, 84 
Perez-Alenza and others 2006). 85 
 86 
Urine cortisol to creatinine ratio and low dose dexamethasone suppression test  87 
(LDDST) are not useful for monitoring disease control following therapy (Angles and 88 
others 1997, Ruckstuhl and others 2002, Braddock and others 2003). Alternative tests 89 
are required because of the expense and availability of synthetic ACTH in certain 90 
countries (Behrend and others 2006). Even in those countries where ACTH is 91 
relatively inexpensive, ACTH stimulation tests do not assess the long term control of 92 
cortisol. Long term control of cortisol is required if HAC is to be successfully 93 
managed. For this reason, a marker that reflects chronic cortisol control (similar to 94 
fructosamine in diabetic patients) would be valuable.  95 
 96 
 97 
The aim of this study was to assess whether control of h peradrenocorticism by 98 
trilostane therapy (defined by post ACTH serum cortisol concentrations) significantly 99 
affected the serum concentration of APPS (Hp, CRP and SAA), ALKP, and 100 
cholesterol. The secondary aim was to determine whether APPS, ALKP and 101 
cholesterol could provide an alternative method of assessing control of canine HAC 102 
treated with trilostane and finally if a combination of these tests analytes offered a 103 
better validity in assessing disease control.   104 
 105 
 106 
Materials and methods 107 
 108 
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Sixteen client-owned dogs were included in the study.  All dogs had clinical signs, 109 
physical examination findings, routine biochemistry and haematology results 110 
consistent with HAC (Herrtage 2004).  The diagnosis was confirmed by an 111 
intravenous ACTH (Synacthen, Alliance Pharmaceuticals Ltd, Whiltshire, UK) 112 
stimulation test and/or failure to suppress cortisol levels following intravenous 113 
administration of low dose dexamethasone and evidence of unilateral or bilateral 114 
adrenal gland enlargement on abdominal ultrasound. ACTH stimulation and LDDS 115 
tests were performed as previously described (Herrtage 2004).  Ethical approval for all 116 
procedures performed on these cases was obtained from a local ethics committee 117 
acting under guidance from the UK Home Office.  118 
 119 
All the analytes were assessed in samples taken before ACTH administration (with 120 
the exception of post ACTH cortisol) at initial presentation and again at 2, 4, 12 and 121 
24 weeks after initiating trilostane therapy (starting dose of 30-60 mg PO q 12-24 h). 122 
For the purposes of this study, control of HAC was defined as a post-ACTH cortisol 123 
concentration below 150 nmol/l (Herrtage 2004, McGrotty and others 2005), with the 124 
test being performed four to six hours after trilostane administration. The analytes 125 
were recorded at the first time point when control was achieved and these results were 126 
then compared to pre-treatment values. Dogs were excluded from the study if control 127 
of HAC was not achieved. Dogs with adrenal dependant hyperadrenocorticism where 128 
also removed from the statistical analysis. None of the dogs were receiving any other 129 
drugs during the study.  130 
 131 
Serum for APPS assessment was collected during routine jugular venipuncture and 132 
frozen at-20° C for batch analysis at a later date. Haptoglobin was measured using a 133 
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method previously reported (McGrotty and others 2003). CRP and SAA were 134 
measured using a microtitre plate reader (Tridelta Development Ltd, Ireland) designed 135 
for use in determining SAA concentrations in various animal species and validated for 136 
canine serum samples in our laboratory. The precisions of the assays were previously 137 
assessed by calculation of the intra- and inter-assay coefficients of variation (CV). 138 
The intra-assay CV was assessed by calculating the CV between duplicates (Fraser 139 
1986), and was found to be 1.82% and 2.85% per cent over duplicate pairs over a Hp 140 
range of 0.29 to 0.72 g/l, 1.0 % and 2.8 % per cent over duplicate pairs over a CRP 141 
range of 18 to 74 µg/ml, and 3 % and 1.2 % per cent over duplicate pairs over a SAA 142 
range of 46.7 to 178 µg/ml. The inter-assay variation was also calculated based on 143 
replicates of control samples on two occasions. The CVs were 5.63 % and 4.83 % 144 
with mean Hp concentrations of 0.28 g/l and 0.73 g/l. For CRP and SAA the inter-145 
assay variations were calculated based on control samples assayed in each assay 146 
performed. The CVs were 11.1 % and 12.6 % with mean CRP concentrations of 19 147 
µg/ml and 75 µg/ml (Mishcke and others 2007), and 26 % and 15 % with mean SAA 148 
concentrations of 56 µg/ml and 189 µg/ml (ReactivLab, University of Glasgow, 149 
Bearsden, Scotland, data on file). 150 
Accuracy was confirmed with serial dilutions between standards and dilutions of 151 
serum from dogs with raised CRP and SAA concentrations. The reference range for 152 
canine Hp using this assay has been previously reported as 0 to 2.2 g/l, while 153 
concentrations above 10 g/l are considered evidence of a major inflammatory 154 
response (Eckersall and others 1999a). The reference range for canine CRP is 0.46-9.6 155 
µg/ml (Mischke and others 2007). The reference range for SAA is 0.08 to 8.75ug/ml 156 
(ReactivLab, data on file).  157 
 158 
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Plasma alkaline phosphatase was measured using a standard assay in a commercial 159 
laboratory (Nationwide Laboratories, Lancashire, UK). The reference ranges for 160 
canine ALKP (0-100 IU/l) and cholesterol (3.9-7.8 mmol/l) used in this study were 161 
provided by the laboratory.  Serum cortisol concentrations before and after ACTH 162 
stimulation where measured using commercially available solid phase 163 
radioimmunoassay kits (Coat-a-Count, DPC) previously validated for use in dogs. 164 
(Cambridge Specialist Laboratory Services Ltd, Cambridge, UK).  165 
 166 
Statistical analyses were conducted using SAS statistical software (release 9.1, © 167 
2002-03, SAS Institute Inc., Cary, NC, USA). A Wilcoxon signed rank test was used 168 
to assess change in the analytes concentration at first presentation (time = 0) 169 
compared to disease control (time =1). This non parametric test was preferred to the 170 
corresponding parametric paired t-test because distributions of differences (significant 171 
difference P< .05) in metabolite concentration showed distribution unlikely to be 172 
normal, an important assumption of the parametric test.  173 
 174 
Receiver-operating characteristic (ROC) curves for Hp, SAA, CRP, ALKP and 175 
cholesterol were plotted using an on-line SAS macro, %ROCPLOT 176 
(http://support.sas.com/kb/25/018.html) to assess for adequate specificity and 177 
sensitivity in the assessment of disease control at various cut-off values of analytes.  178 
Another on-line macro, %ROC (http://support.sas.com/kb/25/017.html) was used for 179 
calculation of areas under ROC curves and their confidence limits. 180 
 181 
Different analyte combinations were then tested in series or parallel after determining 182 
their covariance (Dohoo and others 2003). Sensitivity (Se) and specificity (Sp) at the 183 
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optimal cut off values (maximum Se and Sp) for different analytes was determined 184 
and used to evaluate whether a pair of analytes used in series and/or parallel would 185 
have better discriminating ability.  186 
 187 
Results 188 
 189 
Sixteen dogs of various breeds with spontaneous HAC were included in this study. 190 
Dogs ranged from 6 to 13 years (mean 9.4, median 9.3). Eight were male and 8 191 
female, weight range from 4.2 to 46 kg (mean 20.29, median 15). Eleven were 192 
diagnosed with pituitary dependant HAC and 3 with adrenal dependant HAC. Five 193 
dogs were removed from the study. Three were adrenal dependant, one did not 194 
achieve a post ACTH cortisol <150 nmol/l, and the other due to insufficient 195 
laboratory data. A post ACTH cortisol reduction <150 nmol/ with reduction of 196 
clinical signs was achieved in the remaining 14 dogs that were included in the final 197 
analysis. All dogs except one received trilostane twice daily. The target post ACTH 198 
cortisol <150 nmol/l occurred at week 2 in 6 dogs, at week 12 in 2 dogs and at week 199 
24 in 3 dogs. 200 
 201 
There was a statistically significant reduction in Hp, SAA, ALKP and cholesterol 202 
concentrations pre and post trilostane treatment. However, no statistically significant 203 
difference in pre and post treatment CRP values was found. Before treatment, 100% 204 
of dogs had Hp concentrations above the reference range and 9.09% (1/11) and 18.1% 205 
(2/11) had increased CRP and SAA serum concentrations respectively. After 206 
achieving control 100% (11/11), 18.1% (2/11) and 9.09% (1/11) had Hp, CRP and 207 
SAA concentrations above reference range respectively. All dogs both before and 208 
after treatment with trilostane had increased ALKP concentrations. Cholesterol 209 
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concentrations were increased in 90.9% of dogs (10/11) before and 45.45% (5/11) 210 
after trilostane treatment (Table 1).   211 
 212 
Receiver-operating characteristic (ROC) curves were obtained (Figures 1a and 1b). 213 
Areas under the curves (AUC) and their 95% confidence limits (Table 2) indicate that 214 
the AUC for various analytes ranged from 0.58 to 0.82. Se and Sp at optimal cut off 215 
values determined from ROC curves (Table 2) were greater than 0.7 only for Hp, 216 
Cholesterol and ALKP; other analytes had either Se or Sp lower than 0.7. Therefore, 217 
only combination of Hp, Cholesterol and ALKP was evaluated in series and parallel. 218 
When they were tested in parallel, the combined Se was higher (0.95) but Sp was 219 
lower (0.55). In contrast, Se was lower (0.59) and Sp higher (0.93) when they were 220 
tested in series.  221 
 222 
 223 
Discussion 224 
 225 
This study showed a significant decrease in Hp values after trilostane treatment in 226 
dogs with HAC, although Hp remained above the reference range in all but one dog. 227 
This is in agreement with our previous study (McGrotty and others 2005). To the 228 
authors’ knowledge this is the first report documenting CRP and SAA changes in 229 
dogs with naturally occurring HAC both pre and post trilostane treatment. Although 230 
we found a significant reduction in SAA concentration following control of HAC, this 231 
result has to be interpreted with caution as most dogs in this study had SAA within the 232 
reference range both before and after treatment. As may occur in Hp concentrations, 233 
increase of CRP in one of the dogs of our study following control of the HAC, may be 234 
associated with a concurrent or underlying inflammatory condition that was not 235 
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detectable during clinical examination (Onishi and others 2000, Kobelt and others 236 
2003, Ceron and others 2005, Tecles and others 2005).  237 
 238 
 A variety of diseases have been associated with an increase in Hp (Harvey and West 239 
1987, McGrotty and others 2003, Martinez-Subiela and others 2004). Concurrent 240 
inflammatory conditions reported in dogs with HAC, even after control of disease that 241 
could account for ongoing Hp elevation include pyoderma, urinary tract infection, 242 
osteoarthritis and neoplasia (Feldman and Nelson 2004). These conditions were not 243 
clinically apparent in the study dogs except pituitary or adrenal neoplasia. However 244 
subclinical disease cannot be excluded. Accumulation of endogenous ACTH and 245 
cortisol precursors occurs after trilostane treatment (Siebert-Ruckstuhl and others 246 
2006). Dogs with atypical hyperadr nocorticism and increase blood levels of steroid 247 
hormones other than cortisol may have similar blood biochemical changes (Oliver 248 
2007). Therefore the accumulation of cortisol precursor in dogs treated with trilostane 249 
may also contribute to the elevation of other analytes such as ALKP and Hp. 250 
 251 
Meijer (1980) suggested that ALKP activity was one of the most useful routine 252 
laboratory tests in supporting clinical suspicion of HAC and previous studies have 253 
found a significant reduction of ALKP following trilostane therapy (Ruckstuhl and 254 
others 2002, Perez-Alenza and others 2006). In agreement with these reports, we 255 
found an elevated ALKP in all dogs prior to treatment and significant reduction in 256 
ALKP after treatment, but values remained above the reference range. Short duration 257 
of trilostane activity, enzymatic induction due to accumulation of other cortisol 258 
precursors or presence of concurrent disease processes (Neiger and Hurley 2001, 259 
Dunn and others 1995, Siebert-Ruckstuhl and others 2006) could account for this 260 
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finding. In most dogs with HAC, steroid induced isoform of ALKP (SIALKP) 261 
accounts for 70-90% of the total ALKP activity (Wilson and Feldman 1992). In the 262 
present study only total serum ALKP was assessed. Measuring SIALKP may have 263 
yielded more significant results. Although several studies have analysed SIALKP for 264 
the screening of dogs with HAC (Teske and others 1989, Wilson and Feldman 1992, 265 
Solter and others 1993), there are no previous studies considering the use of either 266 
ALKP or SIALKP as a screening tool to assess control of canine HAC with trilostane 267 
or mitotane treatment.  268 
 269 
In common with ALKP, cholesterol has been shown to be increased in dogs with 270 
HAC (Ling and others 1979, Meijer 1980). In agreement with the findings of our 271 
study, significant reductions in serum cholesterol have been previously reported 272 
following control of HAC with trilostane (Ruckstuhl and others 2002). An 273 
improvement of the lipid enzymatic pathways, as a result of decrease cortisol may 274 
account for the reduction of cholesterol post treatment. The effect of increased 275 
endogenous ACTH and other cortisol precursors (Siebert-Ruckstuhl and others 2006) 276 
is unknown but may account for the ongoing elevation of cholesterol in some of the 277 
study dogs.  278 
 279 
The second aim of this study was to determine whether APPS, ALKP and cholesterol 280 
concentrations could provide an alternative method of assessing control of canine 281 
HAC treated with trilostane. The ACTH stimulation test is currently recommended for 282 
the assessment of control of canine HAC treated either with mitotane (Dunn and 283 
others 1995) or trilostane (Neiger and others 2002, Ruckstuhl and others 2002, 284 
Braddock and others 2003).  The range of post ACTH serum cortisol concentrations 285 
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in which control has been defined for dogs on trilostane varies from 30 to 250 nmol/l 286 
(Neiger and others 2002, Ruckstuhl and others 2002, Braddock and others 2003). We 287 
used an arbitrary post-ACTH cortisol concentration (<150 nmol/l) following a 288 
previous study from our group (McGrotty and others 2005).  289 
 290 
An alternative test is considered accurate, compared with the “gold standard”, when 291 
the AUC is 0.9-1 at a given cut-off point. AUC between 0.7-0.9 is considered only 292 
moderately informative (Greiner and others 2000). Using ROC curves, we found Hp, 293 
Cholesterol and ALKP to be the most useful tools to assess control of disease after 294 
trilostane treatment becaus  their areas under the ROC curve were higher than the 295 
areas of CRP and SAA. When comparing the Hp, Cholesterol and ALKP 296 
concentrations to post-ACTH cortisol concentrations, the maximum sensitivities and 297 
specificities of around 73% were only moderately informative. CRP and SAA are 298 
poor predictors of disease control. This was not unexpected in the case of the CRP 299 
following the lack of significant variation of its concentrations following trilostane 300 
treatment.  301 
 302 
The final aim of the study was to assess whether a combination of analytes offered a 303 
better validity in assessment control of HAC. Combination with CRP and SAA was 304 
not pursued as lower Se and Sp of these analytes was likely to further reduce the Se 305 
and Sp of the combination (Dohoo and others 2003). The combinations of Hp, 306 
Cholesterol and ALKP in parallel and series were not helpful in assessing control of 307 
HAC due to reduction in Sp and Se of the combined test, respectively. 308 
 309 
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There are a number of limitations of this study. The low number of cases may limit 310 
the power of the study but this does not impact on the results found to be significant. 311 
In other words, the differences detected are more likely to be real. A study with a 312 
higher number of cases would be required to further assess the non-significant 313 
findings of this study. Another limitation of this study is the use of a statistical method 314 
to assess adequacy of several analytes based on a gold standard test (ACTH 315 
stimulation test). Therefore when comparing the different analytes with post-ACTH 316 
cortisol results we assume a diagnostic adequacy of this test is 100% (Greiner and 317 
others 2000). However, the ACTH stimulation test is not entirely specific nor 318 
sensitive and assessment of disease control in dogs on trilostane still relays on 319 
concurrent judgement of the clinical evolution of the patient (Braddock and others 320 
2003, Feldman and Nelson 2004). Some other tests for the diagnosis and assessment 321 
of control of HAC such as intramuscular ACTH stimulation test, salivary cortisol and 322 
UCCR following low dexamethasone suppression tests are currently under evaluation 323 
(Kobelt and others 2003, Vaessen and others 2004, Behrend and others 2006).  324 
 325 
We used an arbitrary cut-off for serum cortisol concentration of <150 nmol/l 326 
(Herrtage 2004, McGrotty and others 2005) for control of HAC.  This does not 327 
necessarily equate to full clinical control. Other authors have suggested lower post-328 
ACTH cortisol concentrations (<70 nmol/l) for well-controlled cases (Ruckstuhl and 329 
others 2002). Using of a lower cortisol cut-off may have offered more significant 330 
variations in some of the analytes tested.  A cut off of a post-ACTH cortisol 331 
concentration of less than 15 nmol/l) has been proposed as excessive control of HAC 332 
(Braddock and others 2003).  These dogs are at risk of hypocortisolemia, and 333 
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trilostane dose reduction may be required. None of the dogs of the study had cortisol 334 
values below this point.  335 
 336 
Measurement of APPS, ALKP and cholesterol may be altered by hyperlipidaemia, 337 
hyperbilirubinaemia, and/or haemolysis (Kaplan and Pesce 1996, Martinez-Subiela S, 338 
Ceron 2005). However, no obvious changes were reported by the laboratory in the 339 
analysed samples.  Dogs with an adrenal tumour may have different APPS behaviour 340 
due to the concurrent ongoing inflammatory response due to the tumour itself (Teske 341 
and others 1989), therefore, to avoid the influence of this inflammatory response, they 342 
were excluded from the statistical analysis.  The number of cases with adrenal disease 343 
in our study was too small to analyse this effect. Further studies in a larger cohort of 344 
dogs with adrenal dependant hyperadrenocorticism treated with trilostane are needed 345 
to assess its effect on APPS concentrations. We only evaluated APPS, ALKP and 346 
cholesterol at one defined point of control, which may not explain the behaviour of 347 
the different metabolites over a longer period of time. Futher studies to assess other 348 
APPS such as α1-acid glycoprotein, ceruloplasmin or α1-antiprotease in dogs with 349 
adrenal and pituitary dependant HAC at different stages of control could be useful.  350 
 351 
 352 
In conclusion, the current study revealed significant changes in Hp, SAA, ALKP and 353 
cholesterol concentrations but no significant difference in CRP after control of HAC 354 
with trilostane. Compared with ACTH stimulation test in dogs with HAC on trilostane 355 
treatment, the study analytes were less to only moderately informative even in 356 
combination. Therefore, routine measurement of Hp, CRP, SAA, ALKP and 357 
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cholesterol cannot be recommended to assess control of pituitary dependant 358 
hyperadrenocorticsm in dogs on trilostane treatment.  359 
 360 
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Time 0 Time 1 
            Units Mean Median IQR Range Mean Median IQR Range 
P 
value 
Hp          g/l 8.09 7.45 5.7 2.8-13.6 4.55 4.20 2.30 1.5-8.1 0.0002* 
CRP       µg/ml 4.69 1.58 1.15 0-27.5 6.04 2.05 3.76 0.32-41.5 0.9 
SAA       µg/ml 2.04 1.10 1.95 0-9.5 1.55 0.30 1.08 0-14.9 0.03* 
ALKP     IU/l 1010.15 830.00 470 113-4091 456.92 269.00 406.50 118-2068 0.002* 
Chol     mmol/l 10.18 9.60 3.3 6.7-16.8 7.35 6.70 2.77 4.8-11.5 0.001* 
 
 
 
Table 1:  Concentrations of the different analytes at first presentation (time: 0) and at 
first point of control (time: 1). IQR† indicates interquartile range. Values marked with 
* indicate significant statistical difference (P<.05).  
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  AUC† SE§ 
Confidence 
Limits Cut off Se Sp 
Hp 0.82 0.09 0.62, 1.00 4.80 0.73 0.91 
CRP 0.51 0.13 0.25, 0.77 2.26 0.46 0.82 
SAA 0.69 0.12 0.45, 0.93 0.19 0.64 0.82 
ALKP 0.74 0.12 0.50, 0.97 531.00 0.80 0.73 
Chol 0.82 0.09 0.64, 1.00 6.2 0.60 1.0 
 
 
Table 2: Area under the curves (AUC†) and their 95% confidence limits for the 
different analytes.  SE§ represents standard error. 
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Fig 1a.       Fig 1b. 
 
Figure 1a: Receiver operator characteristic (ROC) curve plots for haptoglobin (Hp) and 
alkaline phosphatase (alkp) after control of hyperadrenocorticism (cortisol post-ACTH< 
150 nml/l).  
Figure 1b: ROC curve plots for C-reactive protein (CRP), serum amyloid A (SAA), and 
cholesterol (Chol) after control of hyperadrenocorticism (cortisol post-ACTH< 150 
nml/l).  
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